Clinical Trials Browser

INDUSTRY × Pituitary Neoplasms × Clear all

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01689727 2023-06-22

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Phase 2 Completed

Pituitary Neoplasms

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT04335357 2020-04-06

TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas

Phase 2 Unknown

Pituitary Neoplasms

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Phase 3 Completed

123 enrolled 27 charts

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01582061 2018-06-19

SEASCAPE

Phase 3 Completed

104 enrolled 22 charts

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01137682 2018-04-05

PAOLA

Phase 3 Completed

198 enrolled 17 charts

Acromegaly, Pituitary Neoplasms

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase 2 Withdrawn

Pituitary Neoplasms

NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Phase 1 Completed

BreastCNSDermatologicEndocrineLymphoidOther hematologic neoplasmSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Craniopharyngioma, Vipoma, Ependymoma, Glioblastoma, Glucagonoma, Hodgkin Disease, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Pituitary Neoplasms, Somatostatinoma, Gastrinoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Carcinoma, Islet Cell, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Growth Hormone-Secreting Pituitary Adenoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Small Cell Lung Carcinoma